This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
CJC-1295 DAC (5 mg) + Ipamorelin (5 mg) Stack
Research reference for CJC-1295 DAC and Ipamorelin, listed as separate 5 mg vials. Evidence on individual compounds should not be treated as proof of combined effects. For research and educational use only.
Quick Reference
What is CJC-1295 DAC (5 mg) + Ipamorelin (5 mg) Stack?
Research overview based on the cited scientific literature.
• Goal: Amplify endogenous GH/IGF-1 secretion through dual GHRH and ghrelin receptor pathways[5].
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze-thaw cycles.
Storage Instructions
Proper storage preserves peptide integrity and efficacy.
• Lyophilized (dry powder): Store at ≤−15 °C (5 °F); preferably ≤−50 °C (−58 °F) for long-term storage[5].
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 3–4 weeks[6].
• Allow vials to reach room temperature before opening to minimize condensation uptake.
• Avoid repeated freeze–thaw cycles of reconstituted solutions.
How is CJC-1295 DAC (5 mg) + Ipamorelin (5 mg) Stack studied?
CJC-1295 DAC functions as a synthetic GHRH analog that stimulates pituitary GH release. Its Drug Affinity Complex (DAC) moiety binds to serum albumin, extending its half-life to approximately 6–8 days and producing sustained, dose-dependent elevations in GH and IGF-1[1]. Ipamorelin is a selective growth hormone secretagogue that activates the ghrelin receptor (GHSR) to trigger rapid GH pulses without significantly affecting ACTH, cortisol, or prolactin[2]. When combined, these peptides act through complementary pathways—GHRH receptor and ghrelin receptor—to synergistically amplify endogenous GH secretion[3].
What does the research report about CJC-1295 DAC (5 mg) + Ipamorelin (5 mg) Stack?
Observations from preclinical and clinical literature on GH secretagogues.
• Body composition: GH secretagogues have demonstrated improvements in lean mass and reductions in fat mass in clinical studies[7].
• Sustained GH/IGF-1 elevation: CJC-1295 DAC produces prolonged elevations lasting 6–11 days per administration[1].
• Selectivity: Ipamorelin does not significantly increase cortisol or ACTH at therapeutic doses[2].
• Tolerability: Both peptides were well tolerated in human studies, with transient injection-site reactions being the most common adverse effect[8].
• Water retention, mild headache, and transient numbness/tingling have been reported with GH-elevating compounds.
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
What are the limitations of the research on CJC-1295 DAC (5 mg) + Ipamorelin (5 mg) Stack?
Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.
